Pfizer said on Friday that its experimental sickle cell disease drug failed to meet the main goal in a late stage trial in ...

Pfizer (PFE) stock slips as a Phase 3 trial failure for its sickle cell disease therapy inclacumab marks the latest setback ...

Pfizer ( PFE -0.18%) was a hot stock during the pandemic, but it has been crashing in recent years. The company's COVID ...

Several workers reported symptoms of being exposed to a substance and some were taken to the hospital. The state is ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Pfizer ( PFE 0.22%) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many income investors, questions about the sustainability of the dividend persist.

Hedge fund Starboard in Q2 took a new position in TripAdvisor (NASDAQ:TRIP) and iShares Russell 2000 ETF (IWM), boosted its positions in Salesforce (NYSE:CRM) and Pfizer (NYSE:PFE) and trimmed its ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

Pfizer, Inc. (PFE) stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance.